Successful treatment of epidermolysis bullosa pruriginosa by dupilumab
The Journal of Dermatology · 2023-06 · 50 (6) · 837-842
DOI: 10.1111/1346-8138.16729 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, online erschienen am 24.01.2023. Verfasst von Xue-Ge Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Mini…. Hauptthemen laut MEDLINE: Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Epidermolysis bullosa pruriginosa (EBP) is a rare variant of dystrophic epidermolysis bullosa caused by COL7A1 gene mutation. Intense pruritus and nodular prurigo‐like lesions are the main features of the disease. To date, the treatment strategies for this condition are not well established. Recent studies have indicated that type 2 inflammation plays a role in the pathophysiology of EBP, suggesting Th2 cytokines could be potential therapeutic targets. In this prospective case series study, we reported three patients with EBP, diagnosed by clinical manifestations, histopathological evaluations, and genetic sequencing, two of whom were treated with dupilumab for 20 weeks. Results showed that the clinical symptoms, pruritus, and quality of life of the patients were significantly improved, as measured by the Epidermolysis Bullosa Disease Activity and Scarring Index, the Visual Analog Scale, and the Children's Dermatology Life Quality Index. Serum immunoglobulin E levels also fell gradually over the 20‐week treatment period. Immunotyping of Th1/2/17 cell subsets in peripheral blood by flow cytometry revealed a higher Th2 but parallel Th1 and Th17 cell subsets in patients compared to healthy controls, and a significant decrease in Th2 and an increase in Th17 cells after dupilumab administration. Of note, after 20 weeks of dupilumab treatment, the expression of type VII collagen in the basement membrane of the skin lesion of the patients significantly increased, which was evidenced by immunofluorescence analysis. No treatment‐related adverse events were documented. Taken together, targeting type 2 inflammation with dupilumab may be an effective and safe treatment option for EBP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, C…
- Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China.
ORCID-Profile: Huan Yang, Hua Wang, Xiaoyan Luo
Zitieren
APA
Wu, X. G., Yan, S., Jiang, J. Q., Zhou, T. T., Fang, X., Yang, H., Bai, X. M., Wang, H., & Luo, X. (2023). Successful treatment of epidermolysis bullosa pruriginosa by dupilumab. The Journal of Dermatology, 50(6), 837-842. https://doi.org/10.1111/1346-8138.16729
Vancouver
Wu XG, Yan S, Jiang JQ, Zhou TT, Fang X, Yang H, et al. Successful treatment of epidermolysis bullosa pruriginosa by dupilumab. The Journal of Dermatology. 2023;50(6):837-842. doi:10.1111/1346-8138.16729
BibTeX
@article{Wu2023,
author = {Wu, Xue-Ge and Yan, Shi and Jiang, Jin-Qiu and Zhou, Tian-Tian and Fang, Xiao and Yang, Huan and Bai, Xiao-Ming and Wang, Hua and Luo, Xiaoyan},
title = {Successful treatment of epidermolysis bullosa pruriginosa by dupilumab},
journal = {The Journal of Dermatology},
year = {2023},
volume = {50},
number = {6},
pages = {837--842},
doi = {10.1111/1346-8138.16729}
}
EUVIMED